Destruxin B (Synonyms: SB 242536,NSC 236580) |
| رقم الكتالوجGC10661 |
يعتبر Destruxin B ، المعزول من الفطريات الممرضة للحشرات Metarhizium anisopliae ، أحد الببتيدات الحلزونية ذات الأنشطة المضادة للحشرات والسرطان
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2503-26-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Destruxin B, a cyclic hexadepsipeptide mycotoxin, has been reported to have insecticidal and phytotoxic activity and can also induce apoptosis.
Mycotoxins has been identified as a class of toxic secondary metabolites produced by organisms of the fungus kingdom and are able to cause disease and death in both humans and animals.
In vitro: The results of a previous study showed that destruxin B exhibited selective and significant time- and dose-dependent inhibitory effects on the viabilities of GNM and TSCCa cells but not on GF cells. These findings indicated that destruxin B was able to induce tumor specific growth inhibition in cancer cells through Bax/Bcl-2-mediated intrinsic mitochondrial apoptotic pathway in both time- and dose-dependent manners [1].
In vivo: Animal study found that the daily subcutaneously administered destruxin B at 0.6-15 mg/kg was safe and effective in inhibiting the growth of CRC cells. In addition, the expression of cleaved poly (ADP-ribose) polymerase, Bax, as well as active caspase-3 were observed with destruxin B treatment. Moreover, the increase in tumor volumes of destruxin B treated groups were significantly lower than those of the mock-treated group [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Huang Liu R, Chen SP, Lu TM, Tsai WY, Tsai CH, Yang CC1, Tzeng YM. Selective apoptotic cell death effects of oral cancer cells treated with destruxin B. BMC Complement Altern Med. 2014 Jun 28;14:207. doi: 10.1186/1472-6882-14-207.
[2] Lee YP, Wang CW, Liao WC, Yang CR, Yeh CT, Tsai CH, Yang CC, Tzeng YM. In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer. Anticancer Res. 2012 Jul;32(7):2735-45.
| Cas No. | 2503-26-6 | SDF | |
| المرادفات | SB 242536,NSC 236580 | ||
| Chemical Name | cyclo[N-methyl-L-alanyl-β-alanyl-(2R)-2-hydroxy-4-methylpentanoyl-L-prolyl-L-isoleucyl-N-methyl-L-valyl] | ||
| Canonical SMILES | O=C(N[C@]([C@@H](C)CC)([H])C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1C)=O)=O)[C@@]2([H])N(CCC2)C([C@@H](CC(C)C)OC(CCNC1=O)=O)=O | ||
| Formula | C30H51N5O7 | M.Wt | 593.8 |
| الذوبان | ≤10mg/ml in dichloromethane,;10mg/ml in methanol;10mg/ml in ethyl acetate | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6841 mL | 8.4203 mL | 16.8407 mL |
| 5 mM | 0.3368 mL | 1.6841 mL | 3.3681 mL |
| 10 mM | 0.1684 mL | 0.842 mL | 1.6841 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *